Ensign Peak Advisors
GTHX

Ensign Peak Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Ensign Peak Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,220
Closed -$125K – 2370
2022
Q2 		$125K Buy
25,220
+17,480
+226% +$96.8K ﹤0.01% 1920
2022
Q1 		$59K Hold
7,740
– – ﹤0.01% 2105
2021
Q4 		$79K Buy
+7,740
New +$98.6K ﹤0.01% 2104

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors's GTHX Position: Q3 2022 in Review

Ensign Peak Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2022, closing a stake of 25,220 shares — an estimated $125K sold.

Ensign Peak Advisors first reported a position in GTHX in Q4 2021 and held it in 3 quarters. The position peaked at $125K in Q2 2022. 104 funds tracked by Wall St. Rank hold GTHX as of Q3 2022.

  • Ensign Peak Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 25,220 G1 Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $125K.
  • Ensign Peak Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $125K in Q2 2022.
  • 104 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.